4. Diabetes mellitus
• Diabetes is a “wonderful” affliction
• not very frequent among men
• being a melting down of the flesh and limbs into
urine.
– patients never stop making water
– disease is chronic
– long period to form
– death speedy
– Life is disgusting and painful; thirst unquenchable;
excessive drinking,
• Its cause is of a cold and humid nature as in
dropsy
Aretaeus the Cappadocian (c. AD 30-90)
7. ADA criteria for the diagnosis of
diabetes mellitus: Case definition
In the absence of unequivocal hyperglycemia,
these criteria should be confirmed by repeat testing on a different day.
The third measure (OGTT) is not recommended for routine clinical use.
1. Symptoms of diabetes plus casual plasma glucose concentration ≥ 200
mg/dl (11.1 mmol/l). Casual is defined as any time of day without regard to time
since last meal. The classic symptoms of diabetes include polyuria, polydipsia,
and unexplained weight loss.
OR
2. FPG ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at
least 8 h.
OR
3. 2-h postload glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. The test
should be performed as described by WHO, using a glucose load containing
the equivalent of 75 g anhydrous glucose dissolved in water.
8. Banting, FG, Best CH. The internal secretion of the
pancreas. J Lab Clin Med, 1922; 7:467-468
Insulin
10. Incidence of Diagnosed Diabetes per 1,000 Population Aged 18–79 Years, by Age, United
States, 1980–2010
From 1980 through 2010, the incidence of diagnosed diabetes increased in adults aged 18–44
years and adults aged 65–79 years. Among adults aged 45–64 years, incidence of diagnosed
diabetes showed little change during the 1980s, but increased beginning in the 1990s through
2010
Centers for Disease Control and Prevention
11. Crude and Age-Adjusted Incidence of Diagnosed Diabetes per 1,000 Population Aged 18–79
Years, United States, 1980–2010
From 1980 to 2010, the crude incidence of diagnosed diabetes increased 161% from 3.3 to
8.6 per 1,000 population. Similarly, the age–adjusted incidence increased 140% from 3.5 to
8.4 per 1,000 population, suggesting that the majority of the change was not due to the aging
of the population. However, from 1980 to 2010, incidence did not increase at a constant rate.
Both crude and age–adjusted incidence remained unchanged in the 1980s, and then
increased in the 1990s through 2010. From 2008 through 2010, both crude and age–adjusted
incidence has shown little change.
Centers for Disease Control and Prevention
12. Estimated prevalence of diagnosed and
undiagnosed diabetes in people aged 20 years
or older, by age group, United States, 2007
2.6
10.8
23.8
0
5
10
15
20
25
20-39 40-59 60+
Age Group
Percent
CDC. National Diabetes Fact Sheet, 2007.
Source: 2003–2006 National Health and Nutrition Examination Survey estimates
of total prevalence (both diagnosed and undiagnosed) were projected to year 2007.
13. Crude and Age-Adjusted Percentage of Civilian, Noninstitutionalized Population with Diagnosed
Diabetes, United States, 1980–2010
From 1980 through 2010, the crude prevalence of diagnosed diabetes increased by 176% (from
2.5% to 6.9%). During this period, increases in the crude and age-adjusted prevalence of
diagnosed diabetes were similar, indicating that most of the increase in prevalence was not
because of changes in the population age structure.
Centers for Disease Control and Prevention
15. Complications of diabetes mellitus
Diabetic ketoacidosis and hyperosmolar (nonketotic) coma
Heart disease and stroke
• Heart disease and stroke: 65 percent of deaths in diabetics.
– Heart disease death rates about 2 to 4 times higher
– Stroke risk 2 to 4 times higher
Blindness
• Diabetes is the leading cause of new cases of blindness among adults and causes
12,000 to 24,000 new cases of blindness each year.
Kidney disease
• Diabetes is the leading cause of kidney failure, accounting for 44 percent of new
cases in 2002.
Nervous system disease
• About 60 to 70 percent of diabetics have mild to severe forms of nerve damage.
– impaired sensation or pain in the feet or hands
– Amputation
16. Some characteristics of chronic diseases
• Person
– Multiple, non-specific risk factors
– Disability prominent
– Impact on quality of life important
– Primary, secondary and tertiary prevention
• Time
– Duration of disease
– Epidemic curve
– Long latency
– Fetal/childhood origin
– Time dependency of risk factors
• Place
– Asynchrony of epidemic in different populations
• Societal
– Expensive half-way technologies
• Medication
• Organ replacement therapy
21. Effect of intensified glycemic control on the risk for any type
of macrovascular event in type 1 and type 2 DM: RCTs
Am Heart J. 2006;152:27-38.
22. EBM clinical practice guidelines:
American Diabetes Association.
Standards of medical care in diabetes.
Diabetes Care 2004; 27 (Suppl. 1): S15–34
23. Amundson GM, O'Connor PJ, Solberg LI, Asche SE, Woods RC, Parker ED, Crain AL. Diabetes care quality:
insurance, health plan, and physician group contributions. Am J Manag Care. 2009 Sep;15(9):585-92.
24. • Increase
• diagnosed diabetes
• who receive formal diabetes education
• glycosylated hemoglobin at least twice a year
• annual dilated eye examination
•annual foot examination
•annual dental examination
•self-blood-glucose-monitoring at least once /day
• Reduce
•diabetes death rate.
•lower extremity amputations
•Undetected microalbuminuria
Healthy People 2020: Objectives
Retained From Healthy People 2010
25. Healthy People 2020: New and modified
Objectives
• Reduce
•the annual number of new cases of
diabetes
•the diabetes death rate
•Among diabetics improve
•glycemic control
•blood pressure control
•lipid control
•Increase % engaged in diabetes prevention
behaviors among at-risk population
26.
27. Copyright restrictions may apply.
Shojania, K. G. et al. JAMA 2006;296:427-440.
Community interventions:
Postintervention Differences in Serum HbA1c Values After Adjustment for Study Bias and
Baseline HbA1c Values
Editor's Notes
Aretaeus (Ἀρεταῖος) "the Cappadocian" (Anatolia, now Turkey)
1st century CE Greek physician
Provides an early description of “diabetes mellitus” , illustrating the existence/awareness of chronic diseases common to modern industrial societies predating the epidemiologic transition in these societies.
Predisposition to DM predates modern societies
Phenotype dependent on gene-environment interaction
Early recognition of DM not atypical. Examples:
Hippocrates of Cos II (4th-5th century BCE) credited with describing
sharp breath consistent with asthma, later elaborated by Galen
sudden paralysis consistent with acute stroke
Edema and shortness of breath consistent with heart failure
Galen (2nd century CE) described breast cancer
Syndrome is derived from the Greek (syndrom concurrence, combination) and describes the joint occurrence of clinically salient symptoms described by the patient, signs elicited on examination and test results.
The symptoms associated with this syndrome can occur in a number of distinct disease states:
Type I DM secondary to immune injury to the pancreatic islet cells
Type 2 DM secondary to progressive pancreatic islet cell failure
Secondary diabetes mellitus
• disorders that disrupt pancreatic function
hemochromatosis secondary to excessive absorption of iron
chronic pancreatitis (multiple causes)
cystic fibrosis due to hereditary defect in epithelial chloride transport
pancreatic trauma
viral infection (mumps)
surgical removal of the pancreas
Liver disease and hepatitis C
• endocrine disorders
acromegaly
Cushing’s syndrome
•medications
thiazide and loop-blocking diuretics
beta blockers
glucocorticoids
antiretrovirals
Mendelian traits
Maturity-onset diabetes of the young (MODY), a variant form of Type 2 diabetes accounting for < 5% of cases (ADA); associated genes include:
MODY1 (hepatic nuclear factor-4alpha or HNF-4alpha)
MODY2 (pancreatic glucokinase or GCK)
MODY3 (HNF-1alpha)
MODY4 (insulin promoter factor-1 or IPF-1)
MODY5 (HNF-1beta)
MODY6 (neurogenic differentiation factor-1 or neuroD1)
Mutations of the insulin receptor gene
PPAR-gamma
DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy and deafness), AKA Wolfram syndrome. Gene: WSF1, protein: wolframin; function: ?
Mitochondrial DNA gene mutation and defects in oxidative phosphorylation (NEJM 2004; 350:664-671 )
Defined clinically by patterns of glucose in blood
Elevated blood glucose (hyperglycemia)
Glycosuria (glucose level exceeds threshold for kidney reabsorption)
Detected by simple blood tests
Random blood glucose
Timed blood glucose
Carbohydrate challenge (glucose tolerance) tests
Monitored as a biomarker of disease control
Banting and Best were the first to isolate an active factor from the pancreas, characterize it as a protein, purify the protein,n use the purified protein to replace endogenous insulin and demonstrate successful control of hyperglycemia.
This extraordinary accomplishment was recognized with the Nobel Prize the year following the reports of this research in J Lab Clin Med.
Anatomic location of pancreas and constituent islets of Langerhans
Histology of islets showing insulin-secreting beta cells (light pink) and darker alpha cells
There are many ways to formulate the risk factors associated with any chronic disease. The Framingham risk factors are formulated largely in terms of characteristics of person. Here we broaden this approach to include:
Genetic predisposition
Familial aggregation (shared genes/environment both candidates)
Maternal environment and perinatal exposures (Fetal origins hypothesis)
General mechanisms: Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med. 2008; 359:61-73.
Diabetes: Barker DJ. The fetal origins of type 2 diabetes mellitus. Ann Intern Med. 1999; 130:322-4.
Adaptation to modern diet and urban environment (obesity and sedentary life style)
Socioeconomic factors that characterize race
Objectives Retained As Is From Healthy People 2010
D HP2020–1: Increase the proportion of persons with diagnosed diabetes who receive formal diabetes education. D HP2020–2: Increase the proportion of adults with diabetes whose condition has been diagnosed. D HP2020–3: Reduce the diabetes death rate. D HP2020–4: Reduce the rate of lower extremity amputations in persons with diabetes. D HP2020–5: Increase the proportion of persons with diabetes who obtain an annual urinary microalbumin measurement. D HP2020–6: Increase the proportion of adults with diabetes who have a glycosylated hemoglobin measurement at least twice a year. D HP2020–7: Increase the proportion of adults with diabetes who have an annual dilated eye examination. D HP2020–8: Increase the proportion of adults with diabetes who have at least an annual foot examination. D HP2020–9: Increase the proportion of persons with diabetes who have at least an annual dental examination. D HP2020–10: Increase the proportion of adults with diabetes who perform self-blood-glucose-monitoring at least once daily. Objectives Retained But Modified From Healthy People 2010
D HP2020–11: Reduce the annual number of new cases of diagnosed diabetes in the population. D HP2020–12: Reduce the death rate among the population with diabetes. Objectives New to Healthy People 2020
D HP2020–13: Improve glycemic control among the population with diagnosed diabetes: D HP2020–14: Increase the proportion of the population with diagnosed diabetes whose blood pressure is under control. D HP2020–15: Improve lipid control among the population with diagnosed diabetes. D HP2020–16: Increase the proportion of people with prediabetes or multiple diabetes risk factors that are engaged in diabetes prevention behaviors.
Objectives Archived From Healthy People 2010
Archived objectives are Healthy People 2010 objectives that are not included in the proposed set of Healthy People 2020 objectives for data, target or policy reasons. HP2010 5-3: Reduce the overall rate of diabetes that is clinically diagnosed.
HP2010 5-16: Increase the proportion of adults with diabetes who take aspirin at least 15 times per month.
Objectives Retained As Is From Healthy People 2010
D HP2020–1: Increase the proportion of persons with diagnosed diabetes who receive formal diabetes education. D HP2020–2: Increase the proportion of adults with diabetes whose condition has been diagnosed. D HP2020–3: Reduce the diabetes death rate. D HP2020–4: Reduce the rate of lower extremity amputations in persons with diabetes. D HP2020–5: Increase the proportion of persons with diabetes who obtain an annual urinary microalbumin measurement. D HP2020–6: Increase the proportion of adults with diabetes who have a glycosylated hemoglobin measurement at least twice a year. D HP2020–7: Increase the proportion of adults with diabetes who have an annual dilated eye examination. D HP2020–8: Increase the proportion of adults with diabetes who have at least an annual foot examination. D HP2020–9: Increase the proportion of persons with diabetes who have at least an annual dental examination. D HP2020–10: Increase the proportion of adults with diabetes who perform self-blood-glucose-monitoring at least once daily. Objectives Retained But Modified From Healthy People 2010
D HP2020–11: Reduce the annual number of new cases of diagnosed diabetes in the population. D HP2020–12: Reduce the death rate among the population with diabetes. Objectives New to Healthy People 2020
D HP2020–13: Improve glycemic control among the population with diagnosed diabetes: D HP2020–14: Increase the proportion of the population with diagnosed diabetes whose blood pressure is under control. D HP2020–15: Improve lipid control among the population with diagnosed diabetes. D HP2020–16: Increase the proportion of people with prediabetes or multiple diabetes risk factors that are engaged in diabetes prevention behaviors.
Objectives Archived From Healthy People 2010
Archived objectives are Healthy People 2010 objectives that are not included in the proposed set of Healthy People 2020 objectives for data, target or policy reasons. HP2010 5-3: Reduce the overall rate of diabetes that is clinically diagnosed.
HP2010 5-16: Increase the proportion of adults with diabetes who take aspirin at least 15 times per month.